Section 5 of 6
Economic information and modeling report
2 evidence topics · 1 source
Modeling overview
Summary
The report contains projected annual U.S. sales of $5 million, $56 million, $227 million, $435 million, and $685 million for 2026 through 2030, respectively. This sales forecast is not a relutrigine budget-impact model and does not provide a payer-specific eligible population, treatment acquisition cost, or incremental budget result.
Relutrigine-specific health technology assessments and systematic reviews
No evidence found.
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.